威奥股份公告，持股5%股东刘萍拟自2026年1月28日至2026年4月27日通过集中竞价方式减持不超过390 万股，占公司总股本不超过1%；减持前持有1965万股，占5%。 ...

格隆汇1月6日丨威奥股份(605001.SH)公布，本次减持计划实施前，刘萍女士持有青岛威奥轨道股份有 限公司无限售条件流通股1965万股，占公司总股本比例的5%。刘萍女士拟通过集中竞价交易方式减持 其所持有的公司股份不超过390万股，自本公告披露之日起15个交易日之后的3个月内（2026年1月28日 至2026年4月27日）。 ...

关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：605001 证券简称：威奥股份 公告编号：2026-001 青岛威奥轨道股份有限公司 三、减持计划相关风险提示 一、减持主体的基本情况 股东名称 刘萍 股东身份 控股股东、实控人及一致行动人 □是 □否 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 □否 其他：/ 持股数量 19,650,000股 持股比例 5% 当前持股股份来源 协议转让取得：19,650,000股 上述减持主体无一致行动人。 1 股东持股的基本情况：本次减持计划实施前，刘萍女士持有青岛威奥 轨道股份有限公司（以下简称"公司"）无限售条件流通股 19,650,000 股，占公司总股本比例的 5%。 减持计划的主要内容:刘萍女士拟通过集中竞价交易方式减持其所持 有的公司股份不超过 3,900,000 股，自本公告披露之日起 15 个交易日 之后的 3 个月内（2026 年 1 月 28 日至 2026 年 4 月 ...

格隆汇1月6日丨威奥股份(605001.SH)公布，本次减持计划实施前，刘萍女士持有青岛威奥轨道股份有 限公司无限售条件流通股1965万股，占公司总股本比例的5%。刘萍女士拟通过集中竞价交易方式减持 其所持有的公司股份不超过390万股，自本公告披露之日起15个交易日之后的3个月内（2026年1月28日 至2026年4月27日）。 ...

智通財經APP訊，威奧股份(605001.SH)發佈公告，公司股東劉萍擬通過集中競價交易方式減持其所持 有的公司股份不超過390萬股，自本公告披露之日起15個交易日之後的3個月內(2026年1月28日至2026年 4月27日)。 ...

南财智讯1月6日电，威奥股份公告，刘萍女士计划通过集中竞价交易方式减持其持有的公司股份不超过 390万股，占公司总股本比例不超过1%。减持期间为2026年1月28日至2026年4月27日，减持原因为个人 资金需求。本次减持计划不会对公司治理、持续性经营等产生影响。 ...

Group 1 - The high-pressure oxygen chamber concept has seen a significant increase of 6.13%, making it the top-performing sector today, with 10 stocks rising, including BeiYikang which hit a 30% limit up, and others like Innovation Medical and International Medicine also reaching their daily limit [1][2] - Major stocks in the high-pressure oxygen chamber sector include Samsung Medical, Weiao Co., and Hangyang Co., which increased by 5.88%, 3.92%, and 3.20% respectively [1][2] Group 2 - The high-pressure oxygen chamber sector attracted a net inflow of 216 million yuan from main funds today, with Innovation Medical leading the inflow at 113 million yuan, followed by International Medicine, Samsung Medical, and Hangyang Co. [2] - The net inflow ratios for key stocks in the sector are as follows: Innovation Medical at 82.52%, International Medicine at 37.34%, and Weiao Co. at 4.50% [3]

Group 1 - The high-pressure oxygen chamber concept has seen a significant increase of 7.01%, ranking second among concept sectors, with 10 stocks rising, including BeiYikang which hit a 30% limit up, and others like International Medicine and Innovation Medical also reaching their limit up [1] - The main inflow of funds into the high-pressure oxygen chamber concept amounted to 389 million yuan, with Innovation Medical receiving the highest net inflow of 256 million yuan, followed by International Medicine and Yingkang Life [2][3] - The net inflow ratios for major stocks in the high-pressure oxygen chamber concept are led by Innovation Medical at 74.84%, International Medicine at 41.60%, and Yingkang Life at 8.97% [3] Group 2 - The top-performing concept sectors today include Brain-Computer Interface with a rise of 13.70%, while the Free Trade Zone saw a decline of 2.93% [2] - Other notable sectors include Blood Oxygen Meters up 5.65% and 2025 Annual Report Pre-Increase up 5.16% [2] - The trading volume and turnover rates for stocks in the high-pressure oxygen chamber concept indicate active trading, with Innovation Medical showing a turnover rate of 3.48% [3]

Core Viewpoint - The report highlights the growth in China's high-speed train production, indicating a significant increase in output and market potential for related companies in the industry [1] Group 1: Industry Overview - According to the National Bureau of Statistics, the production of China's high-speed trains reached 206 units in November 2025, representing a year-on-year increase of 24.1% [1] - From January to November 2025, the cumulative production of high-speed trains in China was 1,722 units, showing a cumulative growth of 9.3% [1] Group 2: Companies Involved - Listed companies in the high-speed rail sector include China CRRC (601766), China Railway Signal & Communication (688009), and others such as Thinking Rail Control (603508) and Beijing-Shanghai High-Speed Railway (601816) [1] - The report by Zhiyan Consulting provides strategic analysis and market outlook for the high-speed rail industry from 2026 to 2032, indicating a focus on operational patterns and future prospects [1]

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：请问公司有碳纤维1.9ATA高压氧舱产品技术吗？ 如果 还没有相关产品，有没有做相应技术储备研发或合作计划？ 威奥股份（605001.SH）12月31日在投资者互动平台表示，公司具备生产碳纤维氧舱产品的技术能力， 并已在部分舱型上有所应用。目前出于安全性考虑以及行业标准的规定，公司目前主要专注在1.5和1.3 大气压氧舱产品。 ...